Peptide record

TPDB13342

MagaininF5W-Lys Antibacterial Anticancer Antiparasitic Toxicity standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13342
MagaininF5W-Lys
Antibacterial Anticancer Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia CancerPPD 2.0
standard
No
A 23-aa standard-residue multi-activity (Antibacterial, Anticancer, Antiparasitic, and other sources) peptide sequence curated from AntiBP3, Peptipedia, and CancerPPD 2.0, with an available 3D structural model.
Sequence
GIGKWLHSAKKFGKAFVGEIMNS
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C116H181N31O29S1
RDCQPTY
GK
2505.96
10.55
5
1
10
+3
0.45
-0.078
72.17
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
2.19
3
Residue Composition
number
2
A
0
R
1
N
0
D
0
C
1
E
0
Q
4
G
1
H
2
I
1
L
4
K
1
M
2
F
0
P
2
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 0 C: 0 E: 1 Q: 0 G: 4 H: 1 I: 2 L: 1 K: 4 M: 1 F: 2 P: 0 S: 2 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
23 reviewed residue count
C116H181N31O29S1 sequence-only estimate (linear, free termini)
2505.96 sequence-only estimate (linear, free termini)
10.55 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
0.45 sequence-only estimate (linear, free termini)
-0.078 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Synthetic Activity
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 16.8 µM
Anticancer
16.8 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

2.8% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
2.8% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Conjugation of Cell-Penetrating Peptides to Antimicrobial Peptides Enhances Antibacterial Activity. | ACS Omega | 2019
Evidence 3 Activity

Activity

97% Killing
Toxicity
100 µM
Cytotoxic
97% Killing | 100 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Improvement of Therapeutic Index by the Combination of Enhanced Peptide Cationicity and Proline Introduction. | ACS Infect Dis | 2020
Evidence 4 Activity

Activity

92% Killing
Toxicity
100 µM
Cytotoxic
92% Killing | 100 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Improvement of Therapeutic Index by the Combination of Enhanced Peptide Cationicity and Proline Introduction. | ACS Infect Dis | 2020
Evidence 5 Activity

Activity

IC50
Toxicity
>=65 µM
Cytotoxic
IC50 | >=65 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Selective anticancer activity of synthetic peptides derived from the host defence peptide tritrpticin. | Biochim Biophys Acta | 2020
Evidence 6 Activity

Activity

IC50
Toxicity
65 µM
Hemolytic Cytotoxic
Hemolytic_activity: RBC: IC50 ≥ 65 µM | Cytotoxicity: PBMC: IC50 ≥ 65 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Biochim Biophys Acta Biomembr. 2020 Aug 1 1862(8):183228.